Literature DB >> 33972830

CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.

Brian I Carr1, Volkan Ince1, Harika Gozukara Bag2, Sertac Usta1, Veysel Ersan1, Burak Isik1, Sezai Yilmaz1.   

Abstract

BACKGROUND: Inflammation and its markers are considered prognostically important for many cancers, including Hepatocellular Carcinoma (HCC). However, it is not really clear which markers are the best. AIMS: To assess in a cohort of prospectively-evaluated HCC patients who were treated with liver transplant and whose survival was known, multiple commonly used inflammatory markers in relation to survival and to both clinical and tumor aggressiveness parameters.
RESULTS: Amongst 330 transplanted HCC patients, CRP was found to be the only significant inflammatory marker for survival, on multivariate Cox regression analysis. NLR, PLR, GGT, AST, ALT and the Glasgow inflammation score were also found to be significant, but on univariate analysis only. CRP was significant in patients with both small (< 5 cm) and large HCCs and in patients with elevated or low Alpha-Fetoprotein (AFP) levels. Comparison of HCC patients with high (>2.5 mg/ dL) compared low serum CRP levels showed significant differences for blood levels of NLR, LMR, Hb, total bilirubin and liver transaminases, as well as Maximum Tumor Diameter (MTD) and percent of patients with Portal Vein Thrombosis (PVT).
CONCLUSIONS: Elevated serum CRP levels were associated with significantly increased MTD and percent of patients with PVT and significantly worse overall survival in HCC patients who were treated by liver transplantation.

Entities:  

Keywords:  CRP; HCC; cox; survival

Year:  2021        PMID: 33972830      PMCID: PMC8106696     

Source DB:  PubMed          Journal:  Clin Pract (Lond)        ISSN: 2044-9038


  24 in total

1.  C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.

Authors:  Brian I Carr; Hikmet Akkiz; Vito Guerra; Oguz Üsküdar; Sedef Kuran; Ümit Karaoğullarından; Salih Tokmak; Tuğsan Ballı; Abdulalh Ülkü; Tolga Akçam; Anıl Delik; Burcu Arslan; Figen Doran; Kendal Yalçın; Engin Altntaş; Ayşegül Özakyol; Mehmet Yücesoy; Halil İbrahim Bahçeci; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necat Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

Review 2.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.

Authors:  M B Pepys; M L Baltz
Journal:  Adv Immunol       Date:  1983       Impact factor: 3.543

Review 3.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

4.  C-reactive protein inhibits expression of N-cadherin and ZEB-1 in murine colon adenocarcinoma.

Authors:  Satoshi Kudo; Hajime Saito; Satoru Motoyama; Tomohiko Sasaki; Kazuhiro Imai; Hayato Konno; Shinogu Takashima; Maiko Atari; Yusuke Sato; Yoshihiro Minamiya
Journal:  Tumour Biol       Date:  2015-04-13

Review 5.  Regulation of the human C-reactive protein gene, a major marker of inflammation and cancer.

Authors:  C Toniatti; R Arcone; B Majello; U Ganter; G Arpaia; G Ciliberto
Journal:  Mol Biol Med       Date:  1990-06

Review 6.  The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors:  Fade Aziz Mahmoud; Nilo I Rivera
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 8.  Inflammatory Mechanisms of HCC Development.

Authors:  Maria Grazia Refolo; Caterina Messa; Vito Guerra; Brian Irving Carr; Rosalba D'Alessandro
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

9.  Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients.

Authors:  Litao Xu; Shulin Yu; Liping Zhuang; Peng Wang; Yehua Shen; Junhua Lin; Zhiqiang Meng
Journal:  Oncotarget       Date:  2017-05-23

Review 10.  Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Mu-Xing Li; Xin-Yu Bi; Zhi-Yu Li; Zhen Huang; Yue Han; Jian-Guo Zhou; Jian-Jun Zhao; Ye-Fan Zhang; Hong Zhao; Jian-Qiang Cai
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more
  1 in total

1.  A Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patients.

Authors:  Brian I Carr; Harika Gozukara Bag; Volkan Ince; Sami Akbulut; Veysel Ersan; Sertac Usta; Burak Isik; Zeki Ogut; Adem Tuncer; Sezai Yilmaz
Journal:  J Gastrointest Cancer       Date:  2021-11-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.